# TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

> **NCT02574663** · PHASE1 · COMPLETED · sponsor: **TG Therapeutics, Inc.** · enrollment: 66 (actual)

## Conditions studied

- Pancreatic Cancer
- Colorectal Cancer
- Rectal Cancer
- Gastric Cancer
- Esophageal Cancer
- Gastrointestinal Stromal Tumor (GIST)

## Interventions

- **DRUG:** TGR-1202
- **DRUG:** nab-paclitaxel + gemcitabine
- **DRUG:** Oxaliplatin + Folinic acid + Fluorouracil
- **DRUG:** Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab

## Key facts

- **NCT ID:** NCT02574663
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-11
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2019-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02574663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02574663, "TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02574663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*